While strategies to supplement vaginal lactobacilli, particularly L. crispatus, may reduce the subsequent posttreatment expansion of BV-associated bacteria, these benefits must be balanced against potential lactobacillus-associated increases in vaginal chemokines, such as IP-10 and MIG. This evidence concerns the gene CXCL9 and bacterial vaginosis.